{"id":10759,"date":"2019-11-12T10:49:58","date_gmt":"2019-11-12T09:49:58","guid":{"rendered":"https:\/\/udic.es\/?p=10759"},"modified":"2024-02-14T15:57:01","modified_gmt":"2024-02-14T14:57:01","slug":"biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial","status":"publish","type":"post","link":"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/","title":{"rendered":"Biogen sol\u00b7licitar\u00e0 l&#8217;aprovaci\u00f3 d&#8217;un nou f\u00e0rmac en Alzheimer inicial"},"content":{"rendered":"<p>&nbsp;<\/p>\n<p class=\"p1\" style=\"text-align: left;\"><span class=\"s1\">El 22\/10\/19 Biogen va anunciar el resultat positiu del seu assaig cl\u00ednic EMERGEIX (en el qual ha participat la UDIC) que ha avaluat Aducanumab (un antic\u00f2s monoclonal anti-alfa sinucle\u00efna) en Alzheimer inicial. S&#8217;ha demostrat efica\u00e7 en l&#8217;alentiment del deteriorament cognitiu (mesurat amb les escales CDR-SB, MMSE, ADAS-cog i ADCS-ADL) i una reducci\u00f3 en la c\u00e0rrega amiloide detectada en el PET (de gaireb\u00e9 un 80%). Els efectes secundaris m\u00e9s freq\u00fcents van ser edema cerebral (asimptom\u00e0tic i transitori en general, detectat en la RM cerebral) i cefalea. Aquestes dades suposen un suport de la hip\u00f2tesi amiloide en aquesta malaltia i un canvi del seu paradigma diagn\u00f2stic i terap\u00e8utic.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; El 22\/10\/19 Biogen va anunciar el resultat positiu del seu assaig cl\u00ednic EMERGEIX (en el qual ha participat la UDIC) que ha avaluat Aducanumab (un antic\u00f2s monoclonal anti-alfa sinucle\u00efna) en Alzheimer inicial. S&#8217;ha demostrat efica\u00e7 en l&#8217;alentiment del deteriorament cognitiu (mesurat amb les escales CDR-SB, MMSE, ADAS-cog i ADCS-ADL) i una reducci\u00f3 en la&#8230;<\/p>\n","protected":false},"author":2,"featured_media":9456,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[131,133],"tags":[],"class_list":["post-10759","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alzeimer-ca-2","category-novetats"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biogen sol\u00b7licitar\u00e0 l&#039;aprovaci\u00f3 d&#039;un nou f\u00e0rmac en Alzheimer inicial - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"description\" content=\"&nbsp; El 22\/10\/19 Biogen va anunciar el resultat positiu del seu assaig cl\u00ednic EMERGEIX (en el qual ha participat la UDIC) que ha avaluat Aducanumab (un\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/ca\/biogen-sol\u00b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen sol\u00b7licitar\u00e0 l&#039;aprovaci\u00f3 d&#039;un nou f\u00e0rmac en Alzheimer inicial - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:description\" content=\"&nbsp; El 22\/10\/19 Biogen va anunciar el resultat positiu del seu assaig cl\u00ednic EMERGEIX (en el qual ha participat la UDIC) que ha avaluat Aducanumab (un\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/ca\/biogen-sol\u00b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-12T09:49:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-14T14:57:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1156\" \/>\n\t<meta property=\"og:image:height\" content=\"762\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tito Surribas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tito Surribas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/\"},\"author\":{\"name\":\"Tito Surribas\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e\"},\"headline\":\"Biogen sol\u00b7licitar\u00e0 l&#8217;aprovaci\u00f3 d&#8217;un nou f\u00e0rmac en Alzheimer inicial\",\"datePublished\":\"2019-11-12T09:49:58+00:00\",\"dateModified\":\"2024-02-14T14:57:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/\"},\"wordCount\":126,\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"image\":{\"@id\":\"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg\",\"articleSection\":[\"Alzeimer\",\"Novetats\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/\",\"url\":\"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/\",\"name\":\"Biogen sol\u00b7licitar\u00e0 l'aprovaci\u00f3 d'un nou f\u00e0rmac en Alzheimer inicial - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg\",\"datePublished\":\"2019-11-12T09:49:58+00:00\",\"dateModified\":\"2024-02-14T14:57:01+00:00\",\"description\":\"&nbsp; El 22\/10\/19 Biogen va anunciar el resultat positiu del seu assaig cl\u00ednic EMERGEIX (en el qual ha participat la UDIC) que ha avaluat Aducanumab (un\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg\",\"width\":1156,\"height\":762,\"caption\":\"UDICEQUIPOMEDICO1\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen sol\u00b7licitar\u00e0 l&#8217;aprovaci\u00f3 d&#8217;un nou f\u00e0rmac en Alzheimer inicial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e\",\"name\":\"Tito Surribas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g\",\"caption\":\"Tito Surribas\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biogen sol\u00b7licitar\u00e0 l'aprovaci\u00f3 d'un nou f\u00e0rmac en Alzheimer inicial - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"&nbsp; El 22\/10\/19 Biogen va anunciar el resultat positiu del seu assaig cl\u00ednic EMERGEIX (en el qual ha participat la UDIC) que ha avaluat Aducanumab (un","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/ca\/biogen-sol\u00b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/","og_locale":"ca_ES","og_type":"article","og_title":"Biogen sol\u00b7licitar\u00e0 l'aprovaci\u00f3 d'un nou f\u00e0rmac en Alzheimer inicial - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","og_description":"&nbsp; El 22\/10\/19 Biogen va anunciar el resultat positiu del seu assaig cl\u00ednic EMERGEIX (en el qual ha participat la UDIC) que ha avaluat Aducanumab (un","og_url":"https:\/\/udic.es\/ca\/biogen-sol\u00b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_published_time":"2019-11-12T09:49:58+00:00","article_modified_time":"2024-02-14T14:57:01+00:00","og_image":[{"width":1156,"height":762,"url":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg","type":"image\/jpeg"}],"author":"Tito Surribas","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Tito Surribas","Temps estimat de lectura":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#article","isPartOf":{"@id":"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/"},"author":{"name":"Tito Surribas","@id":"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e"},"headline":"Biogen sol\u00b7licitar\u00e0 l&#8217;aprovaci\u00f3 d&#8217;un nou f\u00e0rmac en Alzheimer inicial","datePublished":"2019-11-12T09:49:58+00:00","dateModified":"2024-02-14T14:57:01+00:00","mainEntityOfPage":{"@id":"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/"},"wordCount":126,"publisher":{"@id":"https:\/\/udic.es\/#organization"},"image":{"@id":"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg","articleSection":["Alzeimer","Novetats"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/","url":"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/","name":"Biogen sol\u00b7licitar\u00e0 l'aprovaci\u00f3 d'un nou f\u00e0rmac en Alzheimer inicial - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg","datePublished":"2019-11-12T09:49:58+00:00","dateModified":"2024-02-14T14:57:01+00:00","description":"&nbsp; El 22\/10\/19 Biogen va anunciar el resultat positiu del seu assaig cl\u00ednic EMERGEIX (en el qual ha participat la UDIC) que ha avaluat Aducanumab (un","breadcrumb":{"@id":"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg","width":1156,"height":762,"caption":"UDICEQUIPOMEDICO1"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/ca\/biogen-sol%c2%b7licitara-laprovacio-dun-nou-farmac-en-alzheimer-inicial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/ca\/"},{"@type":"ListItem","position":2,"name":"Biogen sol\u00b7licitar\u00e0 l&#8217;aprovaci\u00f3 d&#8217;un nou f\u00e0rmac en Alzheimer inicial"}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]},{"@type":"Person","@id":"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e","name":"Tito Surribas","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/udic.es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g","caption":"Tito Surribas"}}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts\/10759"}],"collection":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/comments?post=10759"}],"version-history":[{"count":6,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts\/10759\/revisions"}],"predecessor-version":[{"id":12184,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts\/10759\/revisions\/12184"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/media\/9456"}],"wp:attachment":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/media?parent=10759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/categories?post=10759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/tags?post=10759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}